Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06059391 · ClinicalTrials.gov registry record · Phase 2
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
A Phase 2 study of Acute Myeloid Leukemia and Chronic Lymphocytic Leukemia, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 216
- Enrollment target
- 3
- Study locations
NCT06059391 is a Phase 2 study of Acute Myeloid Leukemia and Chronic Lymphocytic Leukemia that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 216 participants, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (88% higher). The trial reports 3 study locations across 3 states.
The verdict
NCT06059391, a Phase 2 study of Acute Myeloid Leukemia and Chronic Lymphocytic Leukemia, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 216 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplant. The CMV-MVA Triplex vaccine works by causing an immune response in the donors body to the CMV virus, creating immunity to it. The donor then passes that immunity on to the patient upon receiving the stem cell transplant. Giving the CMV-MVA triplex vaccine to donors may help prevent CMV infection of patients undergoing stem cell transplantation.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Allogeneic Hematopoietic Stem Cell Transplantation
- BIOLOGICAL Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- DRUG Granulocyte Colony-Stimulating Factor
- DRUG Hematopoietic Cell Transplantation Conditioning Regimen
Study Locations (3)
California
- City of Hope Medical Center - Duarte
Georgia
- Northside Hospital - Atlanta
Massachusetts
- DFCI/BWH Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2024-07-12 |
| Est. Completion | 2029-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06059391
The ClinicalTrials.gov registry entry for NCT06059391 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (88% higher). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06059391 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Georgia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06059391 about?
NCT06059391 is a clinical study titled "CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant". This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplant. The...
What is the current status of trial NCT06059391?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 216 participants. The study started on 2024-07-12. Estimated completion is 2029-01-01.
What conditions does trial NCT06059391 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT06059391?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Allogeneic Hematopoietic Stem Cell Transplantation (PROCEDURE), Multi-peptide CMV-Modified Vaccinia Ankara Vaccine (BIOLOGICAL), Granulocyte Colony-Stimulating Factor (DRUG), Hematopoietic Cell Transplantation Conditioning Regimen (DRUG).
Who is sponsoring clinical trial NCT06059391?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06059391 being conducted?
This trial has 3 study locations across California, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
RECRUITING · Phase 2
-
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.